PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval Merck (MSD) Press Release - 4 days
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: A1 - Approval FDA - 5 days
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	trilaciclib Sensitive: B - Late Trials G1 Therapeutics Press Release - 1 week
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline Clin Breast Cancer - 1 week
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	albumin-bound paclitaxel Sensitive: C2 – Inclusion Criteria Clin Breast Cancer - 1 week
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HP + eribulin mesylate Sensitive: C2 – Inclusion Criteria Breast Cancer Res Treat - 1 week
ER positive ER positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials BMC Cancer - 2 weeks
ER Y537S ER Y537S	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor + GDC-9545 Sensitive: D – Preclinical J Med Chem - 2 weeks
TUSC7 overexpression TUSC7 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: D – Preclinical Cancer Manag Res - 2 weeks
TUSC7 overexpression TUSC7 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	paclitaxel Sensitive: D – Preclinical Cancer Manag Res - 2 weeks
HER-2 amplification HER-2 amplification	Breast Cancer Breast Cancer	neratinib Sensitive: A1 - Approval Knight Therapeutics Press Release - 3 weeks
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	neratinib Sensitive: A1 - Approval Knight Therapeutics Press Release - 3 weeks
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials Eur J Cancer - 3 weeks
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials Eur J Cancer - 3 weeks
ANXA6 underexpression ANXA6 underexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	lapatinib Sensitive: C3 – Early Trials Cell Death Dis - 3 weeks
EGFR expression EGFR expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	lapatinib Sensitive: C3 – Early Trials Cell Death Dis - 3 weeks
PD-L1 expression PD-L1 expression	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	docetaxel + doxorubicin hydrochloride + cyclophosphamide oral Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	TAC Sensitive: A1 - Approval
HR positive HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval
ER negative ER negative	Breast Cancer Breast Cancer	toremifene Resistant: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	toremifene Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	albumin-bound paclitaxel Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	trastuzumab + lapatinib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	lapatinib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	docetaxel + doxorubicin hydrochloride Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	docetaxel + capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	capecitabine Sensitive: A1 - Approval
HR positive HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	eribulin mesylate Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	non-pegylated liopsomal doxorubicin Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	trastuzumab/hyaluronidase-oysk Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	olaparib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	bevacizumab Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Triple Negative Breast Cancer Triple Negative Breast Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval
HER-2 positive HER-2 positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	exemestane Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	letrozole Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	anastrozole Sensitive: A1 - Approval
ER negative ER negative	Breast Cancer Breast Cancer	anastrozole Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Breast Cancer Breast Cancer	Zercepac (trastuzumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	ixabepilone Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	leuprorelin depot Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Breast Cancer Breast Cancer	trastuzumab + docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Breast Cancer Breast Cancer	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval

Breast Cancer

Associations(1307)

Associations
(1307)